Trajenta糖安達

Trajenta

linagliptin

Manufacturer:

Boehringer Ingelheim

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Linagliptin
Indications/Uses
Adjunct to diet & exercise to improve glycaemic control in adults w/ type 2 DM as monotherapy when metformin is inappropriate due to intolerance or contraindicated due to renal impairment; or in combination w/ other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.
Dosage/Direction for Use
Administration
May be taken with or without food.
Contraindications
Special Precautions
Should not be used in patients w/ type 1 diabetes or for treatment of diabetic ketoacidosis. When used in combination w/ a sulphonylurea &/or insulin, dose reduction of the sulphonylurea or insulin may be considered. Caution in patients w/ history of pancreatitis. Discontinue if pancreatitis is suspected. Should not restart treatment if acute pancreatitis is confirmed. Discontinue if bullous pemphigoid is suspected. Elderly >80 yr.
Adverse Reactions
Drug Interactions
Decreased steady-state AUC & Cmax w/ rifampicin.
MIMS Class
ATC Classification
A10BH05 - linagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Trajenta FC tab 5 mg
Packing/Price
28's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in